{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:45:07Z","timestamp":1791812707787,"version":"4.3.4"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adults with non-dialysis-dependent chronic kidney disease (CKD), ischemic heart disease (IHD), and hypertriglyceridemia are at high cardiorenal risk; whether starting fenofibrate together with statin therapy is effective and safe in this population is uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a multicenter retrospective cohort study emulating a target trial in the TriNetX Global Collaborative Network (2018\u20132024), 112\u2009003 (28.5%) of 392\u2009969 statin initiators with CKD and hypertriglyceridemia had IHD. Those without dialysis dependence were assigned to statin\u2013fenofibrate combination therapy or statin monotherapy according to fenofibrate initiation within 3 months of the first statin prescription. The main outcomes were expanded major adverse cardiovascular events (MACEs) (acute myocardial infarction, stroke, heart failure, cardiac arrest, or all-cause death) and end-stage kidney disease (ESKD) necessitating dialysis. Propensity score matching yielded 3191 pairs. Cox models estimated hazard ratios (HRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median follow-up was 881 days with combination therapy and 925 days with statin monotherapy. Combination therapy was associated with lower risks of MACE [1472 [46.1%] vs 1576 [49.4%] events; HR, 0.93; 95% confidence interval (CI), 0.86\u20130.99] and ESKD necessitating dialysis (264 [8.3%] vs 335 [10.5%]; HR, 0.79; 95% CI, 0.67\u20130.92). Risks of all-cause mortality (377\u00a0vs. 375), acute myocardial infarction (537\u00a0vs. 570), heart failure (1059\u00a0vs. 1134), stroke (310\u00a0vs. 312), acute kidney injury (825\u00a0vs. 840), and coded safety events were not significantly different between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among selected adults with non-dialysis-dependent CKD, hypertriglyceridemia, and IHD, statin\u2013fenofibrate combination therapy was associated with lower risks of MACE and of ESKD necessitating dialysis, without a significant increase in coded safety events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag343","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:56:23Z","timestamp":1790769383000},"source":"Crossref","is-referenced-by-count":0,"title":["Combined statin and fenofibrate therapy and cardiorenal outcomes in patients with CKD, dyslipidemia, and ischemic heart disease"],"prefix":"10.1093","volume":"19","author":[{"given":"Yen-Chih","family":"Chang","sequence":"first","affiliation":[{"name":"Division of General Medicine, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital , Taipei ,","place":["Taiwan"]},{"name":"Department of Medicine, Fu Jen Catholic University , New Taipei City ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-4689","authenticated-orcid":false,"given":"Ming-Hsien","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Fu Jen Catholic University , New Taipei City ,","place":["Taiwan"]},{"name":"Division of Nephrology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital , Taipei ,","place":["Taiwan"]},{"name":"Data Analytic Group, Department of Digital Medicine, Shin Kong Wu Ho-Su Memorial Hospital , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-1885","authenticated-orcid":false,"given":"Yu-Wei","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Fu Jen Catholic University , New Taipei City ,","place":["Taiwan"]},{"name":"Division of Nephrology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Data Analytic Group, Department of Digital Medicine, Shin Kong Wu Ho-Su Memorial Hospital , Taipei ,","place":["Taiwan"]},{"name":"School of Nursing, National Taipei University of Nursing and Health Sciences , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Tseng","sequence":"additional","affiliation":[{"name":"School of Nursing, National Taipei University of Nursing and Health Sciences , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Chun","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Medicine, Fu Jen Catholic University , New Taipei City ,","place":["Taiwan"]},{"name":"Division of Cardiology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026101208471887000_bib1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"key":"2026101208471887000_bib2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic kidney disease and the global public health agenda: an international consensus","volume":"20","author":"Francis","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2026101208471887000_bib3","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"2026101208471887000_bib4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40620-020-00707-2","article-title":"Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology","volume":"33","author":"Pontremoli","year":"2020","journal-title":"J Nephrol"},{"key":"2026101208471887000_bib5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4093\/dmj.2023.0067","article-title":"Dyslipidemia in patients with chronic kidney disease: an updated overview","volume":"47","author":"Suh","year":"2023","journal-title":"Diabetes Metab J"},{"key":"2026101208471887000_bib6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101208471887000_bib7","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet"},{"key":"2026101208471887000_bib8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4082\/kjfm.2017.38.4.192","article-title":"Effect of fenofibrate medication on renal function","volume":"38","author":"Kim","year":"2017","journal-title":"Korean J Fam Med"},{"key":"2026101208471887000_bib9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.7326\/0003-4819-156-8-201204170-00401","article-title":"New fibrate use and acute renal outcomes in elderly adults: a population-based study","volume":"156","author":"Zhao","year":"2012","journal-title":"Ann Intern Med"},{"key":"2026101208471887000_bib10","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"J Am Med Assoc"},{"key":"2026101208471887000_bib11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/fcp.12435","article-title":"Rhabdomyolysis risk from the use of two-drug combination of antidyslipidemic drugs with antihypertensive and antidiabetic medications: a signal detection analysis","volume":"33","author":"Gosho","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"key":"2026101208471887000_bib12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.26402\/jpp.2022.1.14","article-title":"Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells","volume":"73","author":"Tsubaki","year":"2022","journal-title":"J Physiol Pharmacol"},{"key":"2026101208471887000_bib13","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026101208471887000_bib14","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.2337\/dc11-1811","article-title":"Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants","volume":"35","author":"Mychaleckyj","year":"2012","journal-title":"Diabetes Care"},{"key":"2026101208471887000_bib15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"key":"2026101208471887000_bib16","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1111\/dom.15815","article-title":"Fenofibrate and risk of end-stage renal disease: a nationwide cohort study","volume":"26","author":"Hyun","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026101208471887000_bib17","doi-asserted-by":"publisher","first-page":"1516126","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026101208471887000_bib18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40620-024-02158-5","article-title":"Clinical trial emulation in nephrology","volume":"38","author":"Zoccali","year":"2025","journal-title":"J Nephrol"},{"key":"2026101208471887000_bib19","doi-asserted-by":"publisher","first-page":"e2558192","DOI":"10.1001\/jamanetworkopen.2025.58192","article-title":"Target trial emulation-a unifying approach for causal inference from observational data","volume":"9","author":"Simon-Tillaux","year":"2026","journal-title":"JAMA Netw Open"},{"key":"2026101208471887000_bib20","doi-asserted-by":"publisher","first-page":"20f13681","DOI":"10.4088\/JCP.20f13681","article-title":"Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets","volume":"81","author":"Andrade","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"2026101208471887000_bib21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"key":"2026101208471887000_bib22","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/ije\/dyz261","article-title":"Use of E-values for addressing confounding in observational studies-an empirical assessment of the literature","volume":"49","author":"Blum","year":"2020","journal-title":"Int J Epidemiol"},{"key":"2026101208471887000_bib23","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1038\/s41433-023-02454-7","article-title":"Interpreting results from randomized controlled trials: what measures to focus on in clinical practice","volume":"37","author":"Darzi","year":"2023","journal-title":"Eye"},{"key":"2026101208471887000_bib24","doi-asserted-by":"publisher","first-page":"107440","DOI":"10.1016\/j.cct.2024.107440","article-title":"Comparison of baseline covariate adjustment methods for restricted mean survival time","volume":"138","author":"Hanada","year":"2024","journal-title":"Contemp Clin Trials"},{"key":"2026101208471887000_bib25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"2026101208471887000_bib26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"2026101208471887000_bib27","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3390\/jcm11030768","article-title":"The effect of fibrates on kidney function and chronic kidney disease progression: a systematic review and meta-analysis of randomised studies","volume":"11","author":"Hadjivasilis","year":"2022","journal-title":"J Clin Med"},{"key":"2026101208471887000_bib28","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron"},{"key":"2026101208471887000_bib29","doi-asserted-by":"publisher","first-page":"F323","DOI":"10.1152\/ajprenal.00596.2015","article-title":"Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of AMPK autophagy","volume":"312","author":"Sohn","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026101208471887000_bib30","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"2026101208471887000_bib31","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1210\/clinem\/dgab137","article-title":"Fenofibrate delays the need for dialysis and reduces cardiovascular risk among patients with advanced CKD","volume":"106","author":"Yen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026101208471887000_bib32","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1345\/aph.1Q110","article-title":"Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population","volume":"45","author":"Amend","year":"2011","journal-title":"Ann Pharmacother"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag343\/71559869\/sfag343.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/10\/sfag343\/71559869\/sfag343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/10\/sfag343\/71559869\/sfag343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:47:35Z","timestamp":1791809255000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag343\/8859088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag343","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10,1]]},"article-number":"sfag343"}}